Merck's Keytruda (pembrolizumab) has demonstrated a significant improvement in event-free survival (EFS) when used in the perioperative setting for resectable head and neck squamous cell cancer (HNSCC). The Phase III trial compared perioperative pembrolizumab combined with adjuvant radiation therapy (with or without chemotherapy) to adjuvant radiation therapy (with or without chemotherapy) alone. The results indicated a statistically significant and clinically meaningful improvement in EFS, marking a potential advancement in the treatment of this challenging cancer.
In another significant development, Pfizer announced positive results from a Phase III trial of Talzenna (talazoparib) in combination with Xtandi (enzalutamide) for metastatic castration-resistant prostate cancer (mCRPC). The trial met its primary endpoint, demonstrating a statistically significant improvement in overall survival (OS) compared to enzalutamide alone. This finding offers a new treatment option for patients with mCRPC, where novel therapies are urgently needed to extend survival and improve quality of life.
Breast Density Notification Mandate
The FDA has implemented a new rule requiring healthcare providers to notify women about their breast density. This mandate aims to improve awareness and understanding of breast density's impact on mammography accuracy and breast cancer risk assessment. The American Cancer Society has released an explainer to help patients and providers navigate this new requirement.
Impact of Breast Cancer Treatments on Aging
A recent study from UCLA Health Jonsson Comprehensive Cancer Center suggests that commonly used breast cancer therapies, including chemotherapy, radiation, and surgery, may accelerate biological aging. The research identified increased production of biomarkers associated with aging following these treatments. These findings highlight the importance of considering the long-term effects of cancer treatments and developing strategies to mitigate treatment-induced aging in breast cancer survivors.
